{
    "clinical_study": {
        "@rank": "166358", 
        "arm_group": [
            {
                "arm_group_label": "NU300 and Prevnar 13", 
                "arm_group_type": "Experimental", 
                "description": "NU300 at a single dose of 0.5 mL IM"
            }, 
            {
                "arm_group_label": "ActHIB and Prevnar 13", 
                "arm_group_type": "Active Comparator", 
                "description": "ActHIB at a dose of 0.5 ml IM"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the safety and tolerability of a single booster dose of NU300, co-administered with\n      Prevnar 13\u00ae over a 28 day period following the injection compared to a single booster of\n      ACTHIB co-administered with Prevnar 13\u00ae over a 28 day period following the injection.\n\n      Evaluate the immunogenicity, as determined by anti-PRP polysaccharide response, of a single\n      booster dose of NU300 co-administered with Prevnar 13\u00ae compared to a single booster dose of\n      ActHIB\u00ae co-administered with Prevnar 13\u00ae.\n\n      Evaluate the individual IgG antibody quantitative response to the 13 antigens in Prevnar 13\u00ae\n      following NU300 co-administration with Prevnar 13\u00ae compared to the IgG antibody response to\n      the pneumococcal polysaccharides following ActHIB\u00ae co-administration with Prevnar 13\u00ae 28\n      days following injection."
        }, 
        "brief_title": "A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Infectious Disease", 
        "condition_browse": {
            "mesh_term": [
                "Communicable Diseases", 
                "Infection"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent obtained from the parent or guardian of the subject\n\n          2. Male or female subjects 12-15 months of age at the time of booster vaccination, who\n             had previously received complete primary vaccination series with a licensed Hib\n             product and Prevnar 13\u00ae in accordance with the FDA approved labels.\n\n          3. Subjects for whom the investigator believes that the parent/guardian can and will\n             comply with the requirements of the protocol\n\n          4. Subjects free of obvious health problems as established by medical history and\n             clinical examination before entering the study\n\n        Exclusion Criteria:\n\n          1. Previous booster vaccination against Hib and/or Prevnar 13\u00ae\n\n          2. Any confirmed or suspected Haemophilus influenzae or pneumococcal illness.\n\n          3. Administration of a vaccine not foreseen by the study protocol during the period\n             starting from 30 days before and ending 28 days after administration of study\n             vaccines (before the blood draw at Visit 2).\n\n          4. Chronic administration of immunosuppressants or other immune-modifying drugs within\n             30 days prior to dosing in the study.\n\n          5. Any confirmed or suspected immunosuppressive or immunodeficient condition based on\n             medical history and/or clinical examination.\n\n          6. Early pre-term birth (delivery before 32 weeks).\n\n          7. Major congenital defects or serious chronic diseases, or serious conditions including\n             history of seizures, apnea, etc.\n\n          8. Concurrent participation in another clinical study at any time during the study\n             period or within the previous 6 months in which the subject has been or will be\n             exposed to an investigational or non-investigational product (pharmaceutical product,\n             formula, or device)\n\n          9. Presence of a moderate or severe illness with or without fever at the time of\n             vaccination (fever is defined as a temperature of \u2265 38.0C [100.4F]).\n\n         10. Known history of thrombocytopenia or any coagulation disorder.\n\n         11. Known hypersensitivity to any of the components of the vaccines.\n\n         12. Known hypersensitivity to latex.\n\n         13. The subject is unable to provide an adequate blood draw for immunogenicity assays,\n             and safety panels at Visit 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "15 Months", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732198", 
            "org_study_id": "CP-NU300-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "NU300 and Prevnar 13", 
                "intervention_name": "NU300", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "ActHIB and Prevnar 13", 
                "intervention_name": "ActHIB", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "NU300 and Prevnar 13", 
                    "ActHIB and Prevnar 13"
                ], 
                "intervention_name": "Prevnar 13", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94611"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bardstown", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40004"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Multicenter, Randomized, Double-Blind, Immunogenicity, Reactogenicity, and Safety Study of NU300 Booster Dose Compared to ActHIB\u00ae, Both Co-administered With Prevnar 13\u00ae at 12-15 Months of Age, in Healthy Toddlers Who Have Received a Primary Series of a Licensed Hib Vaccine and Prevnar 13\u00ae", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the safety and tolerability of a single booster dose of NU300, co-administered with Prevnar 13\u00ae compared to a single booster dose of ActHIB\u00ae co-administered with Prevnar 13\u00ae, over a 28 day period following injection\nEvaluate the immunogenicity, as determined by anti-PRP polysaccharide response, of a single booster dose of NU300 co-administered with Prevnar 13\u00ae compared to a single booster dose of ActHIB\u00ae co-administered with Prevnar 13\u00ae.", 
            "measure": "safety and efficacy", 
            "safety_issue": "Yes", 
            "time_frame": "one month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732198"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluate the individual IgG antibody quantitative response to the 13 antigens in Prevnar 13\u00ae following NU300 co-administration with Prevnar 13\u00ae compared to the IgG antibody response to the pneumococcal polysaccharides following ActHIB\u00ae co-administration with Prevnar 13\u00ae 28 days following injection", 
            "measure": "Evaluate the individual IgG antibody quantitative response to the 13 antigens in Prevnar 13\u00ae", 
            "safety_issue": "Yes", 
            "time_frame": "one month"
        }, 
        "source": "Nuron Biotech Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nuron Biotech Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}